PCaP Home

Introduction

Welcome to the official website of the North Carolina-Louisiana Prostate Cancer Project. Prostate cancer is the most common cancer in men and the second leading cause of cancer mortality. In men younger than 65 years of age, the prostate cancer mortality rate for African Americans is 3.1 times that of Caucasian Americans. In men 65 years of age and older, the prostate cancer mortality rate for African Americans is 2.3 times that of Caucasian Americans.

Geographic differences in aggressive prostate cancer within racial groups and differences in mortality rates between North Carolina and Louisiana were the driving factors behind the development of PCaP. PCaP is a multidisciplinary population-based case-only study designed to address racial differences in prostate cancer through a comprehensive evaluation of social, individual and tumor level influences on prostate cancer aggressiveness. At baseline, PCaP enrolled approximately equal numbers of African Americans and Caucasian Americans with newly-diagnosed prostate cancer from Louisiana and North Carolina (2,258 total). In addition to PCaP baseline enrollment, several follow-up studies have been undertaken. For more details of PCaP, click here (PCaP).

The questions the PCaP study addresses are:

Name PCaP HCaP–NC Q-PCaP Financial Toxicity
Timeline 2004-2009 4-6 Years of follow up 10-15 years of follow up
Funding Department of Defense American Cancer Society (ACS) National Institute
of Health (NIH)
National Cancer
Institute (NCI)
R15
Department of Defense
Sample 2,258 PCa participants 805 PCa
participants
~900 PCa
participants
Recontact of participants is ongoing
Location/Sites North Carolina &
Louisiana
North Carolina Louisiana North Carolina &
Louisiana

Are you interested in learning how you can use PCaP data and biospecimens? Hover over the “For Researchers” tab located on the blue menu bar above to learn more about enrollment, specimen collection and data sharing for PCaP and HCaP–NC. For a quick overview of PCaP data click on the link “For Researchers”.